Navigenics Founder Blasts Myriad's BRACAnalysis Pricing | GenomeWeb

On the heels of Angelina Jolie's revelation that she underwent a preventive double mastectomy, a Navigenics founder is taking aim at Myriad Genetics' price for its BRACAnalysis test.

In an op-ed piece appearing in the New York Times, David Agus also calls for legislative changes to bar healthcare companies from having monopolies on technologies that have life and death implications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.